RESUMO
Recently, the availability of total HCV core antigen assay in peripheral blood gains more interest in clinical evaluation of HCV patients. The aims of the present study were to assess the value of total HCV core antigen as a marker of viral replication, to determine the sensitivity of core antigen assay relative to molecular biology technique and to study the clinical value of HCV core antigen in relation to interferon-based treatment. This study included 150 patients sero-positive for antibodies to HCV. Viral load was assessed by both HCV RNA quantitative assay [bDNA] and HCV core antigen quantitative immunoassay [Ortho trak-C assay]. Spearman rank correlation coefficient was used to determine significant correlations among parameters. Of the 150 studied patients, 128 [85%] were positive to HCV RNA assay [bDNA] and 22 [15%] were negative. Have the 128 patients tested positive for HCV RNA, 125 patients tested positive by HCV core antigen assay with a sensitivity of 98%. All patients tested negative for HCV RNA assay [bDNA] gave negative results by HCV core antigen assay with a specificity of 100%. In the 125 patients that were positive in both assays, HCV RNA and total HCV core antigen were significantly related [r = 0.984; p< 0.001]. The relationship between HCV RNA in IU/ml and total HCV core antigen in pg/ml was given by the following equation: Log HCV core antigen = 0.649 x Log HCV RNA - 2.018. It was found that 1 core pg/ml is equivalent to approximately 8000 HCV RNA IU/ml in clinical samples of the studied patients. The correlation between HCV RNA IU/ml and HCV core antigen pg/ml varied around this average ratio when individual samples were considered, with the majority of the ratios lying between 5000 and 13000 HCV RNA IU/ml per core pg/ml. To evaluate the clinical use of total HCV core antigen quantification in the pretreatment assessment and in monitoring the response; to interferon therapy, sera from ten patients who were treated with a combination therapy of interferon alpha-2a and ribavirin had been studied. Serum samples were collected at baseline, 12 weeks after initiating therapy and at the end of treatment to be tested by both assays. There were significant correlations between log HCV RNA titer [IU/ml] and log HCV core antigen [pg/ml] [r = 0.693. 1.0 and 1.0 for the three comparisons respectively; p< 0.031. 0.003. and 0.017 respectively]. A weak relation had been found between necro-inflammatory changes in liver biopsy and viral load assessed by both assays. No relation could be found with the stage of liver fibrosis. In conclusion, the HCV core antigen assay can be used in confirming HCV infection when antibodies have been detected, in screening of patients, and in monitoring therapeutic interventions